Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ICCC Stock Summary
In the News
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023
Conference Call Scheduled for Wednesday, February 28, 2024 at 9:00 AM ET Conference Call Scheduled for Wednesday, February 28, 2024 at 9:00 AM ET
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023
Conference Call Scheduled for Tuesday, November 14, 2023 at 9:00 AM ET Conference Call Scheduled for Tuesday, November 14, 2023 at 9:00 AM ET
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023
PORTLAND, Maine, Aug. 07, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended June 30, 2023 after the market closes on Thursday, August 10, 2023. The Company has scheduled a conference call the next morning, Friday, August 11, 2023, at 9:00 AM ET to review its second quarter financial results.
ImmuCell Corporation (ICCC) Q1 2023 Earnings Call Transcript
ImmuCell Corporation (NASDAQ:ICCC ) Q1 2023 Earnings Conference Call May 12, 2023 9:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Michael Brigham - President and CEO Conference Call Participants Operator Good morning, and welcome to ImmuCell Corporation Reports First Quarter 2023 Unaudited Financial Results Conference Call. All participants will be in a listen-only mode.
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2023
PORTLAND, Maine, May 04, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2023 after the market closes on Thursday, May 11, 2023. The Company has scheduled a conference call the next morning, Friday, May 12, 2023, at 9:00 AM ET to review its first quarter financial results.
ImmuCell Corporation (ICCC) Q4 2022 Earnings Call Transcript
ImmuCell Corporation (NASDAQ:ICCC ) Q4 2022 Earnings Conference Call February 22, 2023 9:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Michael Brigham - President and CEO Conference Call Participants Operator Good morning, and welcome to ImmuCell Corporation Reports Fiscal Year 2022 Unaudited Financial Results Conference Call. All participants will be in a listen-only mode.
ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2022
Conference Call Scheduled for Wednesday, February 22, 2023 at 9:00 AM ET Conference Call Scheduled for Wednesday, February 22, 2023 at 9:00 AM ET
ImmuCell Corporation (ICCC) Q3 2022 Earnings Call Transcript
ImmuCell Corporation (NASDAQ:ICCC ) Q3 2022 Earnings Conference Call November 22, 2022 9:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Michael Brigham - President and CEO Bobbi Jo Brockmann - Vice President, Sales and Marketing Conference Call Participants Jim Barrett - Barrett Investments Operator Good morning. And welcome to ImmuCell Corporation Reports Third Quarter Fiscal Year 2022 Financial Results Conference Call.
ImmuCell to Participate in the Lytham Partners Fall 2022 Investor Conference
PORTLAND, Maine, Sept. 14, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, announced today it will participate in the Lytham Partners Fall 2022 Investor Conference taking place virtually on September 28-29, 2022.
ImmuCell Corporation (ICCC) CEO Michael Brigham on Q2 2022 Results - Earnings Call Transcript
ImmuCell Corporation (NASDAQ:ICCC ) Q2 2022 Earnings Conference Call August 12, 2022 9:00 AM ET Company Participants Joe Diaz - Investor Relations Michael Brigham - President and Chief Executive Officer Conference Call Participants George Melas - MKH Management Operator Good morning. This is Anthony from Chorus Call and I will be assisting with our conference call this morning.
ICCC Financial details
ICCC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 2.01 | 2.13 | 2.53 | 2.4 | 2.26 | |
Net income per share | -0.19 | -0.14 | -0.01 | -0.32 | -0.75 | |
Operating cash flow per share | 0.03 | 0.18 | 0.13 | -0.2 | 0.35 | |
Free cash flow per share | -0.17 | -0.38 | -0.22 | -0.71 | 0.35 | |
Cash per share | 1.65 | 1.24 | 1.34 | 0.75 | 0 | |
Book value per share | 4.25 | 3.92 | 4.29 | 3.92 | 0 | |
Tangible book value per share | 4.22 | 3.89 | 4.27 | 3.9 | 0 | |
Share holders equity per share | 4.25 | 3.92 | 4.29 | 3.92 | 0 | |
Interest debt per share | 1.3 | 1.55 | 1.39 | 1.66 | 0 | |
Market cap | 35.12M | 42.92M | 60.74M | 47.25M | 39.44M | |
Enterprise value | 34.77M | 45.71M | 60.83M | 53.93M | 39.44M | |
P/E ratio | -27.1 | -42 | -778.71 | -18.94 | -6.83 | |
Price to sales ratio | 2.56 | 2.8 | 3.16 | 2.54 | 2.26 | |
POCF ratio | 150.39 | 32.62 | 63.66 | -30.6 | 14.62 | |
PFCF ratio | -30.33 | -15.57 | -36.71 | -8.56 | 14.62 | |
P/B Ratio | 1.21 | 1.52 | 1.86 | 1.56 | 0 | |
PTB ratio | 1.21 | 1.52 | 1.86 | 1.56 | 0 | |
EV to sales | 2.53 | 2.98 | 3.16 | 2.9 | 2.26 | |
Enterprise value over EBITDA | -36.44 | -33.12 | 236.69 | -23.46 | -13.11 | |
EV to operating cash flow | 148.88 | 34.74 | 63.75 | -34.93 | 14.62 | |
EV to free cash flow | -30.02 | -16.58 | -36.77 | -9.77 | 14.62 | |
Earnings yield | -0.04 | -0.02 | 0 | -0.05 | -0.15 | |
Free cash flow yield | -0.03 | -0.06 | -0.03 | -0.12 | 0.07 | |
Debt to equity | 0.29 | 0.38 | 0.32 | 0.41 | 0 | |
Debt to assets | 0.22 | 0.27 | 0.23 | 0.28 | 0 | |
Net debt to EBITDA | 0.37 | -2.02 | 0.35 | -2.91 | 0 | |
Current ratio | 5.29 | 5.5 | 6.42 | 4.56 | 0 | |
Interest coverage | -2.21 | -3.34 | -7.01 | -6.74 | 0 | |
Income quality | -0.18 | -1.29 | -12.19 | 0.62 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.12 | 0.11 | 0.09 | 0.12 | 0 | |
Research and developement to revenue | 0.27 | 0.28 | 0.22 | 0.24 | 0.25 | |
Intangibles to total assets | 0.01 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | -5.96 | -3.1 | -2.73 | 2.57 | 0 | |
Capex to revenue | -0.1 | -0.27 | -0.14 | -0.21 | 0 | |
Capex to depreciation | -0.61 | -1.74 | -1.06 | -1.6 | 0 | |
Stock based compensation to revenue | 0.02 | 0.02 | 0.01 | 0.01 | 0 | |
Graham number | 4.26 | 3.53 | 1 | 5.33 | 0 | |
ROIC | -0.03 | -0.03 | -0.06 | -0.05 | 0 | |
Return on tangible assets | -0.03 | -0.03 | 0 | -0.06 | 0 | |
Graham Net | 0.6 | -0.1 | 0.25 | -0.56 | 0 | |
Working capital | 10.69M | 9.95M | 13.73M | 10.92M | 0 | |
Tangible asset value | 28.78M | 28.07M | 32.41M | 30.23M | 0 | |
Net current asset value | 3.49M | 73.01K | 4.38M | -486.24K | 0 | |
Invested capital | 0.29 | 0.38 | 0.32 | 0.41 | 0 | |
Average receivables | 1.55M | 1.77M | 2.29M | 2.26M | 900.39K | |
Average payables | 587.96K | 587.26K | 673.7K | 767.52K | 395K | |
Average inventory | 2.42M | 2.31M | 2.59M | 4.56M | 3.02M | |
Days sales outstanding | 44.62 | 44.36 | 51.61 | 35.4 | 0 | |
Days payables outstanding | 29.91 | 25.93 | 25.69 | 26.41 | 0 | |
Days of inventory on hand | 131.63 | 90.08 | 106.53 | 201.86 | 0 | |
Receivables turnover | 8.18 | 8.23 | 7.07 | 10.31 | 0 | |
Payables turnover | 12.2 | 14.08 | 14.21 | 13.82 | 0 | |
Inventory turnover | 2.77 | 4.05 | 3.43 | 1.81 | 0 | |
ROE | -0.04 | -0.04 | 0 | -0.08 | 0 | |
Capex per share | -0.2 | -0.56 | -0.34 | -0.51 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.5 | 0.44 | 0.46 | 0.7 | 0.66 | |
Net income per share | -0.22 | -0.3 | -0.18 | -0.12 | -0.15 | |
Operating cash flow per share | -0.17 | -0.36 | -0.09 | -0.07 | 0 | |
Free cash flow per share | -0.36 | -0.44 | -0.18 | -0.12 | 0 | |
Cash per share | 0.75 | 0.4 | 0.19 | 0.26 | 0.13 | |
Book value per share | 3.92 | 3.64 | 3.47 | 3.36 | 0 | |
Tangible book value per share | 3.9 | 3.62 | 3.45 | 3.34 | 5.65 | |
Share holders equity per share | 3.92 | 3.64 | 3.47 | 3.36 | 0 | |
Interest debt per share | 1.62 | 1.72 | 1.96 | 2.17 | 0 | |
Market cap | 47.26M | 39.97M | 38.73M | 41.37M | 39.45M | |
Enterprise value | 53.94M | 50.1M | 52.38M | 56.06M | 38.47M | |
P/E ratio | -7.08 | -4.32 | -7.02 | -11 | -8.65 | |
Price to sales ratio | 12.08 | 11.6 | 10.96 | 7.67 | 7.74 | |
POCF ratio | -36.41 | -14.47 | -56.84 | -81.47 | 0 | |
PFCF ratio | -16.95 | -11.61 | -27.87 | -44.56 | 0 | |
P/B Ratio | 1.56 | 1.42 | 1.44 | 1.59 | 0 | |
PTB ratio | 1.56 | 1.42 | 1.44 | 1.59 | 0 | |
EV to sales | 13.79 | 14.54 | 14.83 | 10.39 | 7.55 | |
Enterprise value over EBITDA | -31.11 | -32.15 | -86.32 | -47.35 | -120.97 | |
EV to operating cash flow | -41.57 | -18.14 | -76.87 | -110.41 | 0 | |
EV to free cash flow | -19.35 | -14.55 | -37.69 | -60.39 | 0 | |
Earnings yield | -0.04 | -0.06 | -0.04 | -0.02 | -0.03 | |
Free cash flow yield | -0.06 | -0.09 | -0.04 | -0.02 | 0 | |
Debt to equity | 0.41 | 0.47 | 0.56 | 0.64 | 0 | |
Debt to assets | 0.28 | 0.31 | 0.34 | 0.37 | 0 | |
Net debt to EBITDA | -3.86 | -6.5 | -22.49 | -12.41 | 3.08 | |
Current ratio | 4.56 | 3.19 | 2.61 | 3.59 | 0 | |
Interest coverage | -19 | -25.07 | -15.05 | -8.71 | 0 | |
Income quality | 0.78 | 1.19 | 0.49 | 0.54 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.15 | 0.16 | 0.15 | 0.1 | 0 | |
Research and developement to revenue | 0.27 | 0.32 | 0.31 | 0.21 | 0.21 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 1.15 | 0.25 | 1.04 | 0.83 | 0 | |
Capex to revenue | -0.38 | -0.2 | -0.2 | -0.08 | 0 | |
Capex to depreciation | -2.47 | -1.04 | -1.03 | -0.6 | 0 | |
Stock based compensation to revenue | 0.02 | 0.03 | 0.02 | 0.02 | 0 | |
Graham number | 4.36 | 4.94 | 3.73 | 3.03 | 0 | |
ROIC | -0.04 | -0.05 | -0.03 | -0.03 | 0 | |
Return on tangible assets | -0.04 | -0.05 | -0.03 | -0.02 | -0.03 | |
Graham Net | -0.56 | -0.92 | -1.39 | -1.46 | 0.13 | |
Working capital | 10.92M | 8.41M | 6.75M | 8.63M | 979K | |
Tangible asset value | 30.23M | 28.01M | 26.71M | 25.87M | 43.81M | |
Net current asset value | -486.24K | -2.71M | -6.2M | -6.57M | 979K | |
Invested capital | 0.41 | 0.47 | 0.56 | 0.64 | 0 | |
Average receivables | 1.77M | 1.97M | 1.83M | 1.77M | 1M | |
Average payables | 774.67K | 792.43K | 856.63K | 849.12K | 389.92K | |
Average inventory | 5.68M | 6.18M | 6.93M | 7.46M | 3.69M | |
Days sales outstanding | 41.44 | 55.94 | 38.77 | 33.51 | 0 | |
Days payables outstanding | 24.36 | 22.74 | 33.21 | 17 | 0 | |
Days of inventory on hand | 186.21 | 181.05 | 272.52 | 160.96 | 0 | |
Receivables turnover | 2.17 | 1.61 | 2.32 | 2.69 | 0 | |
Payables turnover | 3.69 | 3.96 | 2.71 | 5.3 | 0 | |
Inventory turnover | 0.48 | 0.5 | 0.33 | 0.56 | 0 | |
ROE | -0.05 | -0.08 | -0.05 | -0.04 | 0 | |
Capex per share | -0.19 | -0.09 | -0.09 | -0.05 | 0 |
ICCC Frequently Asked Questions
What is ImmuCell Corporation stock symbol ?
ImmuCell Corporation is a US stock , located in Portland of Me and trading under the symbol ICCC
What is ImmuCell Corporation stock quote today ?
ImmuCell Corporation stock price is $5.3918 today.
Is ImmuCell Corporation stock public?
Yes, ImmuCell Corporation is a publicly traded company.